Unjha Formulations Ltd (UNJHAFOR) is currently trading at 28.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Unjha Formulations Ltd is a prominent manufacturer of pharmaceutical formulations including liquids, powders, tablets, capsules, and injectables. They are pioneers in Ayurvedic Isabgol products. The company operates two major divisions for human and veterinary products, making it one of the largest Isabgol product manufacturers in India. It possesses a state-of-the-art manufacturing facility certified with a GMP certificate, ensuring high-quality production standards. Unjha Formulations Ltd has successfully tapped into export markets, contributing to its growth, with a new direction in areas like Ferrous Sulphate and Iron Folic Tablets. A notable strategic move includes their manufacturing agreement with Nicholas Piramal India Ltd for Fybogel, indicating strategic partnership capabilities.

Over the past 52 weeks, Unjha Formulations Ltd has traded between a low of ₹17.52 and a high of ₹36.38. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Unjha Formulations Ltd has a market capitalization of approximately 12.66. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Unjha Formulations Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 74.47 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 12.66 Cr, Unjha Formulations Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Unjha Formulations Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Unjha Formulations Ltd is 74.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Unjha Formulations invested Rs 1.50 crore in fixed deposits during the half year ended 30 September 2026. Its total investing cash outflow was Rs 1.5711 crore, while net operating cash inflow was Rs 8.28 lakh, leaving Rs 15.43 lakh of closing cash and cash equivalents.

Unjha Formulations reported unaudited profit of Rs 66.70 lakh for the half year ended September 30, 2026. That was down from Rs 120.78 lakh in the corresponding half year ended September 30, 2025. The company reported no current or deferred tax expense in either period.

Unjha Formulations reported net profit of ₹0.16 crore, or ₹15.69 lakh, for the quarter ended June 2026. This was down 59.76% from ₹0.39 crore in the June 2025 quarter.

Unjha Formulations reported a net profit of ₹15.69 lakh for Q1FY27 (quarter ended June 30, 2026).